Delcath Systems (DCTH) said Monday that the US Food and Drug Administration cleared its investigational new drug application for a phase 2 clinical trial of Hapzato, in combination with standard of care, in liver-dominant metastatic colorectal cancer.
The trial will evaluate the safety and efficacy of the combination therapy, with a primary endpoint of hepatic progression-free survival that is expected to be read out by the end of 2027, according to the company.
Delcath Systems said it expects to enroll about 90 patients for the study and plans to start enrollment in the second half of 2025.
Price: 11.76, Change: -0.13, Percent Change: -1.05
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。